Cell Therapeutics Inc., of Seattle, received a patent for a class of small-molecule antitubulin agents with anti-proliferative and tumor-killing activity, including lead compound CT-45099

Genmab A/S, of Copenhagen, Denmark, received a patent for HuMax-HepC, a fully human antibody in preclinical development to prevent re-infection with the hepatitis C virus after liver transplantation

Solbec Pharmaceuticals Ltd., of Perth, Australia, received a patent, titled "Rhamnose Binding Protein," covering the generation of compounds targeting RPB, a receptor that is overexpressed on cancer cells

Acorda Therapeutics Inc., of Hawthorne, N.Y., received a patent on its neuregulins products, covering compositions of matter for the NRG2 family of growth factors, as well as methods of production for NRG2

Cortex Biochem Inc. , of Raleigh, N.C., received a patent for its MagaZorb Nucleic Acid (DNA/RNA) Isolation and Purification System

BioVisioN AG, of Hanover, Germany, received a patent, "Differential Peptide Display," covering its core technology for the discovery and identification of peptide biomarkers

Pharmaxis Ltd., of Sydney, Australia, received a patent for a possible treatment for multiple sclerosis, extending intellectual property protection for its autoimmune disease research

Biophan Technologies Inc., of Rochester, N.Y., received a patent to secure the rights to its anti-antenna technology for use in magnetic resonance imaging procedures

DermTech International Inc., of San Diego, received a patent allowance for an application titled "Methods for Obtaining and Analyzing Skin Samples for the Detection of Nucleic Acids

AntiCancer Inc., of San Diego, received a patent covering the use of fluorescent proteins for the imaging of cancer, gene expression, stem cells and other processes in animals, as well as humans

AMDL Inc., of Tustin, Calif., received a patent for its Combination Immunogene Therapy, which uses two genes in combination to build a body's immune system and destroy cancer cells...Bio-America Inc., of Toronto, received a patent titled "A Method to Control Lipogenesis," which refers to a way to control production of fat reserves by regulating the levels of human proteins called lipogenins

Peplin Biotech Ltd., of Brisbane, Australia, received a patent allowance to include the use of angeloyl-substituted ingenanes in broadly treating cancer, extending the scope of protection afforded by a prior patent that protects the use of angeloyl-substituted ingenanes in treating skin cancer

Serologicals Corp., of Atlanta, received a patent on its purification process, which inactivates infectious prions in its bovine-based Ex-Cyte cell culture growth supplement

Lorus Therapeutics Inc., of Toronto, received a patent allowance titled "Antisense Oligonucleotide Sequences as Inhibitors of Microorganisms

diaDexus Inc., of Santa Clara, Calif., said it received a patent covering a method for the diagnosis of a patient's susceptibility to atherosclerosis using antibodies against Lp-PLA2

It is being developed for the treatment and prevention of epilepsy, migraine and mania. * Aquasearch Inc., of Kailua-Kona, Hawaii, received a patent, "Process and Apparatus for the Production of Photosynthetic Microbes," in Hong Kong for its microalgae production technology, the Aquasearch Growth Module. * Ariad Pharmaceuticals Inc., of Cambridge, Mass., announced that the Massachusetts Institute of Technology, also of Cambridge, received patent No

5,801,029, covering the use of modified adenoviruses and adenoviral compositions, and other DNA viruses, which lack viral proteins that bind to the tumor suppressor protein Rb to treat cancer patients whose tumors lack Rb function. * Targeted Genetics Corp., of Seattle, and the University of Pittsburgh received a patent protecting a new class of lipid-based systems that can be used as vehicles for efficient gene delivery

Oncor Inc., of Gaithersburg, Md., received a notice of allowance for its Sunrise Amplification Detection System for the direct quantitative analysis of DNA amplificat ion products. * SciClone Pharmaceuticals Inc., of San Mateo, Calif., received a notice of allowance for a patent covering the use of the firm's lead drug, thymosin alpha 1, to treat hepatitis C. * Sepracor Inc., of Marlborough, Mass., received patent No

5,786,161 covers isolation and characterization of allergen-binding cells for diagnosis of hypersensitivity. * Anergen Inc., of Redwood City, Calif., received patent No...Re35748, also covers the use of such compositions in treating neopastic or hyperproliferative lesions. * MediChem Research Inc., of Lemont, Ill., received patent No